Rapport Therapeutics

RAPP

市值 US$13.2億

Rapport Therapeutics stock fell ~18% as investors digested updates on lead candidate RAP-219 and anticipated Phase 2 bipolar mania data. RAP-219 shows strong efficacy in focal onset seizures, with up to 90% median reduction in clinical seizures, supporting optimism for Phase 3 success. Analysts remain focused on the FOS opportunity, viewing the upcoming bipolar mania readout as potentially more instructive for safety than efficacy.

Biotech stocks widely slumped Wednesday, with Rapport Therapeutics, Climb Bio and Cullinan Therapeutics among some of the hardest-hit names.

Rapport Therapeutics, Inc. (RAPP) Discusses RAP-219 Phase II Trial and Unmet Needs in Bipolar Mania Transcript

KOD, CLDX, RAPP and PCVX face key clinical readouts this fall that could influence their drug and vaccine pipelines.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

BOSTON and SAN DIEGO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in the following upcoming investor events: Cantor Global Healthcare Conference (New York City) – fireside chat on Wednesday, September 9, 2026, at 1:35-2:05 pm ET.

BOSTON and SAN DIEGO, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, September 22, 2026, at 12:30 PM ET. To register for the event, please click here.

Rapport Therapeutics is differentiated by RAP-219's neuroanatomically selective pharmacology and a 22-day half-life, supporting a bullish outlook. RAPP is fully funded through pivotal Phase 3 trials, with $436.1M in cash expected to last into 2H 2029, but it will likely need more capital before commercial launch. RAP-219's long half-life offers a 'forgiveness' advantage for missed doses, but regulatory scrutiny is expected regarding safety during prolonged exposure.

RAP-219 Phase 3 program in focal onset seizures initiated, with FOCUS 1 and FOCUS 2 trials enrolling patients RAP-219 Phase 2 trial in bipolar mania on track for topline results in October 2026 Pipeline continues to advance, including the RAP-219 long-acting injectable and primary generalized tonic-clonic seizures program, and the RAP-641 α6β4 nAChR program in chronic pain and migraine Ended the second quarter of 2026 with $436.1 million in cash, cash equivalents and short-term investments, excluding restricted cash, expected to fund operations into the second half of 2029 BOSTON and SAN DIEGO, Aug. 05, 2026 (GLOBE NEWSWIRE) --  Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today reported financial results for the quarter ending June 30, 2026, and highlighted continued progress across the RAP-219 development program and pipeline. "We remain focused on disciplined execution as we deliver against several important catalysts this year," said Abraham N.

COO Cheryl Gault sold 10,000 shares on June 30, 2026, for a transaction value of ~$416,000, based on a weighted average price of $41.58 per share. This sale represented 6.2% of Gault's direct holdings, reducing her position from 159,914 to 149,914 shares.